Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Inclusion Criteria:

1. T3-4NxM0 locally advanced gastric or gastroesophageal junction carcinoma was confirmed by gastroscopic biopsy, CT and pathological examination;
2. No previous systematic treatment for the current disease;
3. Age ≥ 70 years, age ≥18 years, both sexes;
4. ECOG physical status score 0-1; Full organ and bone marrow function:
5. Blood routine: hemoglobin ≥90g/L, neutrophil count ≥1.5×10\^9/L, platelet count ≥75×10\^9/L; Liver function: serum total bilirubin ≤1.5× upper normal value (UNL), aspartate transferase ≤3×UNL, alanine Acid transferase ≤3×UNL; Renal function: serum creatinine ≤1.5×UNL, creatinine clearance rate ≥50ml/min; Coagulation function: INR, APTT and PT ≤1.5×UNL; Serum albumin ≥30g/L; Thyrotropin (TSH) and free thyroxine (fT4) were within the range of normal ±10%.

   Electrocardiogram showed no obvious abnormality.
6. Not receiving blood transfusion, blood products, or blood cell growth factors such as granulocyte colony-stimulating factor within 2 weeks;
7. Sign an informed consent form before starting the study on a specific screening procedure;
8. The estimated survival time is more than 3 months;
9. Subjects volunteered to join this study, with good compliance, safety and survival follow-up -

Exclusion Criteria:

Patients with any of the following were excluded from the study:

1. People with allergic disease, history of severe drug allergy, known allergy to macromolecular protein preparations or carrelizumab;
2. Early gastric cancer;
3. Gastric cancer patients with HER2 amplification by pathological gene detection;
4. History of other malignancies (except cured basal cell carcinoma of the skin, cured cervix) with disease-free survival \<5 years Carcinoma in situ and gastrointestinal neoplasms proven to be cured by endoscopic mucosal resection);
5. The presence or history of any active autoimmune disease (including but not limited to: interstitial pneumonia, Uveitis, enteritis, nephritis, hyperthyroidism, hypothyroidism);
6. You are using immunosuppressive agents or hormone therapy (systemic or topical) to achieve immunosuppression, and Continued to use within 2 weeks before enrollment;
7. Severe infection (if intravenous antibiotics, antifungal or antiviral drugs are needed);
8. Congenital or acquired immune deficiency (such as HIV-infected persons), or active hepatitis ((with regular antiviral treatment)